Bridgewater Associates LP Lowers Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Bridgewater Associates LP decreased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 78.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,872 shares of the company’s stock after selling 17,324 shares during the quarter. Bridgewater Associates LP’s holdings in TransMedics Group were worth $765,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Driehaus Capital Management LLC grew its stake in TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after acquiring an additional 30,092 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its position in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after acquiring an additional 64,360 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after acquiring an additional 6,634 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $85.14 on Tuesday. The company’s fifty day simple moving average is $110.21 and its two-hundred day simple moving average is $135.81. TransMedics Group, Inc. has a 12-month low of $68.84 and a 12-month high of $177.37. The firm has a market cap of $2.86 billion, a PE ratio of 90.57 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.12) earnings per share. As a group, equities analysts expect that TransMedics Group, Inc. will post 1.01 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Oppenheimer reduced their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $131.80.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,958 shares of company stock valued at $3,470,328. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.